Last checked at 7 May 2024 20:22
TRADING UPDATES: Abingdon Health buys IVDeology Holdings
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Allergy Thera. Share News (AGY)
AGY Share
Price
AGY Share
News
AGY Share
Chat
AGY Share
Trades41
AGY
Live RNS
AGY Share
Charts
AGY Level 2
Console
AGY Live
Share Price
AGY Broker
Ratings
AGY Directors
Deals
AGY Financial
Diary
AGY
Fundamentals
AGY Short
Positions
AGY
Media
Allergy Thera. Information
Share Price Information for Allergy Thera. (AGY)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.075
Bid:
2.95
Ask:
3.20
Change:
0.245 (8.52%)
Spread:
0.25 (8.475%)
Open:
2.875
High:
3.12
Low:
2.875
Prev. Close:
2.875
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Allergy Therapeutics sees good first-half progress
Wed, 16th Jan 2019 08:51
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.The AIM-traded firm said reported revenues for the six month period were expected to be £46.7m, representing 10.6% growth on both a reported and constant currency basis.In terms of geography, the main contributors to that sales growth were Germany, Austria, Switzerland and Netherlands.Allergy said its Spain operations had continued to grow "well", despite the withdrawal of all bacterial products across the market.In terms of product mix, the growth was being driven primarily by its ultra-short course, aluminium-free treatments 'Pollinex' and 'Pollinex Quattro', as well as 'Acarovac' and 'Venomil'.The group said it continued to gain market share in Germany, and again achieved the number one position in that market for the month of October - Allergy's busiest month of the year - for the second year running.Its cash balance at the end of December was £31.6m, up from £25.8m year-on-year.Allergy Therapeutics said it continued to make "good progress" with the peanut allergy vaccine outsourced manufacturing scale-up, and the Acarovac Phase I trial for dust mite allergies.The first in-human trials for the Polyvac peanut product were expected to start in 2019, with data from the Acarovac Phase I trial expected in the first half of 2019.As it announced in December, the top-line results of the PQ Birch Phase III trial would be announced in the first quarter of 2019.Meetings with the FDA and the German regulator, the Paul-Ehrlich-Institut (PEI), in relation to the PQ Grass trials were also scheduled for the first quarter, the board confirmed. "This is another period of revenue growth and continued gain in market share for Allergy Therapeutics, in line with our mid and long-term strategy," said chief executive officer Manuel Llobet."The group is also making good progress across its clinical pipeline, with a number of key developments anticipated for the first half of this year."We see momentum in the business and look forward to updating the market at our interim results."Allergy Therapeutics said it would announce its half-year results on 6 March.
More News
27 Mar 2024 16:13
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more27 Mar 2024 11:02
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more12 Mar 2024 14:06
Allergy Therapeutics starts dosing patients in peanut allergy trial
(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.
Read more1 Mar 2024 15:49
UK shareholder meetings calendar - next 7 days
| Monday 4 March | |
| Ascent Resources PLC | GM re bonus issue of preference shares |
| JPMorgan Emerging Europe, Middle East & Africa Securities PLC | AGM |
| Lexington Gold Ltd | AGM |
| Tuesday 5 March | |
| Ajax Resources PLC | GM re extension of investment mandate |
| Beowulf Mining PLC | GM re capital raise |
| CC Japan Income & Growth Trust PLC | AGM |
| Driver Group PLC | AGM |
| Edinburgh Worldwide Investment Trust PLC | AGM |
| Jersey Electricity PLC | AGM |
| Wednesday 6 March | |
| Ecofin Global Utilities & Infrastructure Trust PLC | AGM |
| Mila Resources PLC | AGM |
| Paragon Banking Group PLC | AGM |
| Thursday 7 March | |
| Asia Strategic Holdings Ltd | AGM |
| CT UK Capital & Income Investment Trust PLC | AGM |
| Henderson Opportunities Trust PLC | AGM |
| XPS Pensions Group PLC | GM re directors' remuneration policy 2024 |
| Friday 8 March | |
| Allergy Therapeutics PLC | AGM |
| All Things Considered Group PLC | AGM |
| Chenavari Toro Income Fund Ltd | AGM |
| Neo Energy Metals PLC | AGM |
| Schroder UK Mid Cap Fund PLC | AGM |
| Silverwood Brands PLC | GM re proposed share capital reduction |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
14 Feb 2024 10:22
Allergy Therapeutics forecasts revenue drop but trials going well
(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.
Read more5 Feb 2024 14:09
TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more30 Jan 2024 10:38
Allergy Therapeutics resumes trading on AIM; annual revenue plunges
(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.
Read more27 Dec 2023 14:17
IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue
Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.
Read more15 Dec 2023 21:09
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more13 Dec 2023 10:11
Allergy Therapeutics shares jump as hails grass allergy jab data
(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.
Read more13 Dec 2023 09:55
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more14 Nov 2023 11:56
Allergy Therapeutics says allergy therapy trial meets primary endpoint
(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.
Read more14 Nov 2023 10:59
AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more